Table 3.
Outcomes of included clinical trials.
| Study |
Number of Patients |
Atrial Fibrillation (%) |
All-Cause Mortality (%) |
Mortality due to CVDs (%) |
Heart Failure (%) |
Hospitalization for Heart Failure (%) |
Stroke (%) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single | Dual | Total | Single | Dual | Single | Dual | Single | Dual | Single | Dual | Single | Dual | Single | Dual | |
| Schwaab 2001 [23] |
8 | 11 | 19 | 0 | 45 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Lamas 2002 [24] |
996 | 1014 | 2010 | 27.1 | 21.4 | 20.5 | 19.7 | 9.2 | 8.5 | 12.3 | 10.3 | 12.3 | 10.3 | 4.9 | 4 |
| Toff WD 2005 [15] |
1009 | 1012 | 2021 | 3.05 | 2.8 | 7.2 | 7.4 | 4.5 | 3.9 | 3.2 | 3.3 | N/A | N/A | 2.1 | 1.7 |
| Ouali S 2009 [25] |
30 | 30 | 60 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Nielsen JC 2011 [26] |
707 | 708 | 1415 | 28.4 | 23 | 29.6 | 27.3 | N/A | N/A | N/A | N/A | N/A | N/A | 5.5 | 4.8 |
| Riahi S 2012 [27] |
707 | 708 | 1415 | N/A | N/A | N/A | N/A | N/A | N/A | 24 | 23.9 | 3.8 | 4 | N/A | N/A |
| Kılıçaslan B 2012 [28] |
30 | 30 | 60 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |